Vaccine Industry Excellence Asia Awards 2011 - The categories

Category:

Nominees:

NEW! Most Innovative Asian Biotech Excellence Award

Open to: All Asian biotechs

This award aims to promote and drive change through the adoption of innovative technologies to develop new vaccines. This company must have exemplified an expansive and agile approach in their vaccine development. The company will also be evaluated based on how the organization has implemented new processes, technology or applications that create quantifiable and sustainable results in the vaccine development process.

Judging criteria:

• Developed a code of conduct/standards for its own organisation that target innovative efforts towards developing new vaccines
• Unconventional best practices that demonstrate business progress and successful integration of business functions and resource optimisation
• Creative ways of collaboration with external suppliers to jointly develop and strengthen relationships
• Pioneering initiatives with measurable components - Results are evaluated against KPIs 

• Panacea Biotec

• Sinovac

• Vaxine

 

» Vote now

NEW! Best Therapeutic Vaccine for Asia Award
(approved or in development)

Open to: Global and Asian pharmaceutical and biotech companies only

This award aims to recognize a company that has set the strategy of developing specific vaccines to address the unmet medical needs in Asia. The company consistently designs better ways to leverage on their skills and technology to increase the research and development of specific therapeutic areas, and through strategic alliances, to facilitate the development of therapeutic vaccines.  

Judging criteria:

• Candidates addressing current unmet medical needs
• Significant potential for vast geographical and market reach
• Possession of a novel mode of action or technology
• Progress through clinical trials and achieved milestones
• Strong safety and risk management data 

• Immunitor

• Novavax

• Ondek

» Vote now

Best Contract Research Organization Excellence Award

Open to: CROs that provide services to Asia

This award aims to recognize the best contract research organization that has demonstrated an ongoing commitment to improve their vaccines clinical research services in Asia and in reducing maximizing lead times for its customers. The CRO must demonstrate an end-to-end suite of solutions to customers and demonstrate outstanding thought leadership in spearheading clinical research innovations and raising the bar of clinical research standards in the region.

Judging criteria:

• Range of services provided in niche and core therapeutic areas
• Methods of performance improvement or introduction of new services to Asia
• Attention to and quality of relationships with clients in Asia
• Reaching of milestones and final / ongoing outcomes
• Building and maintaining existing and long term partnerships in Asia

• Paraxel

• PPD

• Quintiles

» Vote now

Vaccine Executive of the Year Award

Open to: Global and Asian biotech companies only

This award serves to recognise the achievements of an outstanding individual from a biotech in the vaccine development space. The individual must have successfully spearheaded and driven the vaccine development initiatives, taking the company to the next level of excellence. Aside from a proven track record, broad and deep knowledge and length of service in the industry is required. This individual is forward-thinking and innovative in his/her approach to evolving vaccine development issues and challenges, and who has continuously made significant contributions in driving the company’s business objectives throughout past and present market paradigms. 

Judging criteria:

• Degree of outstanding commitment to disease prevention and treatment
• Level of exemplary leadership throughout the year
• Contribution to company performance, communication and vision
• Influence within the industry
• Achievements made with regards to company positioning and status

• Christopher A. Viehbacher,
  Sanofi-Aventis

• Cyrus Poonawalla,
  Serum Institute of India

• Yin Weidong,
  Sinovac

» Vote now

Best Vaccine Pipeline for Asia Award

Open to: Global and Asian pharmaceutical and biotech companies only

This award serves to recognise companies that have demonstrated their commitment to continually develop a strong vaccine R&D pipeline for the Asian markets. The company will be evaluated based on the size, range, and the development phases of the overall vaccine pipeline, and also the novelty of the vaccines. This company is forward-looking and is able to present a pipeline that has a great future market potential and value in Asia Pacific.

Judging criteria:

• Size and range of overall vaccine pipeline
• Mix across development phases
• Spread across innovation and lower risk candidate development
• Commitment to R&D productivity model implementation
• Current and future market potential and value for the pipeline

• GSK

• Novartis

• Sanofi-Pasteur

» Vote now